Summary
A slide rule has been devised which is based on the general mathematical models of pharmacokinetics. It permits calculation of exact dosage regimens for individual patients from certain basic parameters. First, from the patient's renal clearance, the proportionality constant characterizing renal excretion of a certain drug (a) and its non-renal rate constant of elimination (k nr), the rate constant of total elimination (k e) can be calculated. Second, fromk e, the apparent volume of distribution (V d) and the desired final mean concentration of a drug (c∞), exact values can readily be obtained for the loading dose (D*) and the dosage schedule, which consists of the maintenance dose (D), the dosing intervals (τ) and the infusion rate for intravenous administration. In addition the slide rule provides information about the rate at which c∞ is reached ifD alone is administered at τ, and the fluctuation in the concentration around c∞ to be anticipated during τ. By use of this calculation, the slide rule facilitates the decision whether a loading dose should be given, and what dosage schedule is best suited to the therapeutic problem. It is possible, therefore, to calculate exact dosage regimens for individual patients, even for those with excretory dysfunction. The slide rule should also help physicians to comprehend the nature and significance of pharmacokinetic mechanisms.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dettli, L., Spring, P., Ryter, S.: Multiple dose kinetics and drug dosage in patients with kidney disease. Acta Pharmacol. (Kbh)29, Suppl. 3, 211 (1971)
Dettli, L.: Multiple dose elimination kinetics and drug accumulation in patients with normal and with impaired kidney function. In: Advances in the Biosciences 5. Schering Workshop on Pharmacokinetics, Berlin, 8./9. 5. 69, pp. 39–54, Raspé, G. (ed.) Oxford-London-New York-Braunschweig: Pergamon Press, Vieweg 1970
Dost, F.H.: Grundlagen der Pharmakokinetik. Stuttgart: Georg Thieme 1968
Höffler, D.: Antibakterielle Therapie bei Niereninsuffizienz. Beecham Pharma GmbH Mainz 1971
Krüger-Thiemer, E., Bünger, P.: Kumulation und Toxizität bei falscher Dosierung von Sulfanilamiden. Drug Res.11, 867 (1961)
Krüger-Thiemer, E.: Die Lösung chemotherapeutischer Probleme durch programmgesteuerte Ziffernrechenautomaten. 5. Mitteilung: Systematik der pharmakokinetischen Modelle und Interpretation der Verteilungsvolumina und der Geschwindigkeitskonstanten. Drug Res.14, 1334 (1964)
Kramer, P., Horenkamp, J., Willms, B., Scheler, F.: Das Kumulationsverhalten verschiedener Herzglykoside bei Anurie. Dtsch. med. Wschr.95, 444 (1970)
Mitzkat, H.J., Bronsert, U.: Formeln zur vereinfachten Berechnung des Glykosid-Wirkspiegels in der Herztherapie. Int. J. clin. Pharmacol.6, 88 (1972)
Bättig, P.: Ein elektronischer Simulator zur Demonstration pharmakinetischer Konzentrationsverläufe. Drug Res.22, 603–606 (1972)
Patentgesuch: Verfahren zur Berechnung pharmakokinetischer Größen und Gerät zur Ausübung des Verfahrens. Copies will be sent on request
Bättig, P., Schmitt, H.: Aus Analogrechnersimulation abgeleitete Formeln und damit entwickelte Rechenschieberhilfe zur Berechnung pharmakokinetischer Größen (1971). Unpublished, copies will be sent on request.
Rechenscheibe für die pharmakokinetische Beziehung: Endkonzentrationsschwankung zu Dosisintervall, Invasionskonstante und Eliminationskonstante. In preparation
Walz, D., Brune, K.: The relevance of the absorption-rate in pharmacokinetics. In preparation
Reubi, F.: Blutspiegel, Ausscheidung und Dosierung von N-pyrrolidino-methyl-tetracyclin (PMT, Reverin®) bei Nierenkranken. Klin. Wschr.45, 133 (1967)
Kabins, S.A., Cohen, S.: Cephaloridine therapy as related to renal function. Antimicrob. Agents and Chemother.5, 922 (1965)
Kunin, C.M., Atul, N.: Excretion of cephaloridine and cephalotin in patients with renal impairment. New Engl. J. Med.274, 654 (1966)
Pryor, J.S., Joekes, A.M., Foord, R.D.: Cephaloridine excretion in patients with normal and impaired renal function. Postgrad. med. J.43, suppl. 82 (1967)
Dengler, H.J., Bodem, G., Wirth K.: Pharmacokinetic and metabolic studies with lanatoside C, α- and β-acetyldigoxin and digoxin in man. 5th International Congress of Pharmacology, San Francisco, 23.–28. 7. 72
Doherty, J.E., Flanigan, W.J., Perkins, W.H., Ackermann, G.L.: Studies with tritiated digoxin in anephric human subjects. Circulation35, 298 (1967)
Doherty, J.E., Perkins, W.H., Wilson, M.C.: Studies with tritiated digoxin in renal failure. Amer. J. med.37, 536 (1964)
Jelliffe, R.W.: A mathematical analysis of digitalis kinetics in patients with normal and reduced renal function. Math. Biosci.1, 305 (1967)
Gingell, I.C., Waterworth, P.M.: Dose of gentamycin in patients with normal renal function and renal impairment. Brit. med. J.1968 II, 19
Kunin, C.M. Finland M.: Persistence of antibiotics in blood of patients with acute renal failure. III. Penicillin, streptomycin, erythromycin and kanamycin. J. clin. Invest.38, 1509 (1959)
Bünger, P., Diller, W., Führ, J., Krüger-Thiemer, E.: Vergleichende Untersuchungen an neueren Sulfanilamiden. 1. Mitteilung. Drug Res.11, 247 (1961)
Krüger-Thiemer, E.: Die experimentelle Bewertung neuer Sulfanilamide als Vorbereitung ihrer klinischen Prüfung. Klin. Wschr.40, 153 (1962)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bättig, P., Brune, K., Schmitt, H. et al. A pharmacokinetic slide rule for more accurate drug treatment. Eur J Clin Pharmacol 7, 233–239 (1974). https://doi.org/10.1007/BF00560386
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00560386